Seagate Technology Holdings plc shares have delivered exceptional returns in 2026, fueled by robust demand for high-capacity data storage solutions driven by artificial intelligence infrastructure expansion, prompting analysts to maintain overwhelmingly positive recommendations and raise price targets amid record margins and revenue growth.

The storage solutions leader, known for its hard disk drives essential to cloud computing and hyperscale data centers, reported strong fiscal third-quarter 2026 results in late April, with revenue reaching $3.11 billion, up 44% year-over-year, and non-GAAP diluted earnings per share of $4.10, exceeding expectations. Gross margins hit record levels around 47%, reflecting operational efficiency and favorable product mix shifts toward higher-value AI-related storage.

As of early June 2026, the stock has climbed dramatically year-to-date, trading near all-time highs despite occasional pullbacks from profit-taking and insider sales. Wall Street consensus remains firmly in the Buy camp, with roughly 20 out of 25 analysts recommending purchase and price targets averaging around $870, with highs reaching $1,150.

Seagate’s performance benefits from the explosive growth in AI workloads, which require massive amounts of storage for training and inference. The company’s heat-assisted magnetic recording (HAMR) technology positions it as a leader in next-generation high-density drives, offering advantages in capacity and cost per terabyte that competitors struggle to match at scale.

Recent analyst actions underscore confidence. Mizuho raised its price target to $1,090 from $875, while BofA increased to $1,000 from $900 and Citi to $1,150 from $740, citing strengthening storage demand and margin outlook. Barclays and Wells Fargo also lifted targets, reflecting sector-wide optimism around AI tailwinds.

“Seagate is poised for continued growth with strong demand in both Data Center and Edge/IoT revenue, as well as the implementation of HAMR technology,” analysts noted in consensus commentary.

The company’s fiscal 2026 trajectory shows accelerating momentum. Earlier quarters reported revenue of $2.63 billion in Q1 and $2.83 billion in Q2, with consistent margin expansion and free cash flow generation supporting dividends and share repurchases. Seagate increased its quarterly dividend to $0.74 per share and has returned substantial capital to shareholders.

Despite the rally, risks remain. The stock experienced an 8% drop in mid-May following CEO comments on capacity expansion timelines, highlighting execution challenges in a cyclical industry. Insider selling by executives, including the CEO, has drawn attention, though such activity often occurs during strong performance periods.

Seagate also reached a $175 million settlement over Huawei-related litigation, providing closure on a lingering issue without materially impacting operations. The company continues to navigate geopolitical tensions affecting global supply chains.

For investors weighing buy or sell decisions in the second half of 2026, the bull case centers on sustained AI investment by major cloud providers. Hyperscalers like Amazon, Microsoft and Google are expected to ramp data center builds, driving multi-year demand for Seagate’s enterprise drives. Analysts project further revenue growth and margin stability as HAMR volumes increase.

Valuation metrics show the stock trading at elevated multiples compared to historical averages, with forward price-to-earnings around 20x amid strong growth forecasts. However, compared to peers in the memory and semiconductor space benefiting from similar AI trends, Seagate’s valuation appears reasonable given its cash flow profile and dividend yield.

Bears point to potential cyclical downturns if AI spending moderates or economic conditions tighten. Competition from Western Digital and solid-state drive alternatives could pressure pricing, though HDDs maintain dominance for bulk storage. Balance sheet leverage and sensitivity to commodity prices add volatility.

Longer-term forecasts for 2026 and beyond remain constructive. Some models project prices exceeding $1,000, contingent on execution and market conditions. The next earnings report, expected in late July, will provide further clarity on guidance and AI momentum.

Seagate’s strategic focus on mass-capacity storage aligns with secular trends in cloud, big data and machine learning. The company’s Singapore headquarters and global operations support efficient manufacturing, while investments in research and development bolster its technological edge.

Market sentiment has improved markedly in 2026, with the stock benefiting from broader technology sector enthusiasm. Trading near the top of its 52-week range and above key moving averages, momentum indicators favor continuation, though overbought conditions warrant caution for short-term entries.

For retail investors, Seagate offers exposure to the critical infrastructure underpinning AI without the extreme valuations of some pure-play semiconductor names. The dividend provides income alongside growth potential, appealing to balanced portfolios.

Analysts emphasize monitoring quarterly results for signs of sustained demand. Key metrics include data center revenue trends, gross margin trajectory and management commentary on capacity and pricing. Positive surprises could drive further upside, while shortfalls might trigger corrections in this high-beta name.

Broader industry context supports optimism. Peers like Micron have achieved trillion-dollar market caps on memory demand, underscoring the value of storage in the AI ecosystem. Seagate’s role as a foundational supplier positions it well for multi-year tailwinds.

Risk management remains essential. Investors should consider position sizing given volatility, diversification across technology subsectors and awareness of macroeconomic factors influencing capital expenditure cycles. Dollar-cost averaging on dips could mitigate timing risks.

Seagate Technology’s transformation from a traditional hard drive manufacturer to a key enabler of the AI revolution has resonated with investors and analysts alike. With strong fundamentals, technological leadership and favorable secular trends, the consensus leans toward buying or holding shares for 2026, though careful monitoring of execution and market dynamics is advised.

As the company prepares for its fiscal fourth quarter and full-year results, attention will focus on whether AI momentum can offset any cyclical pressures. For now, the trajectory points to continued strength in a data-hungry world.

Zentia, which has two sites in Gateshead, is a former North East Business Awards winner

Scores of jobs have been lost at a Gateshead ceiling manufacturer which has been placed into administration amid challenging trading.

Zentia – formerly known as Armstrong Ceiling Solutions until a rebranding exercise when it was acquired in 2020 – employs a significant number of staff across two facilities in Gateshead, where it manufactures ceilings for contractors, architects and interior designers across the UK.

However, in common with a number of other companies operating across the building and construction supply chain, the firm’s two companies – Zentia Limited and Zentia Profiles – have battled challenging trading conditions recently, with the adverse impact of high energy prices impacting production costs. Zentia, which claimed the Made in Britain Award at the North East Business Awards in 2023, also saw sales fall lower than forecast.

Now Will Wright and James Lumb of Interpath have now been appointed joint administrators to Zentia Limited and Zentia Profiles Limited, with both citing the firms’ prolonged struggle against adverse trading conditions.

A statement from Interpath details how, in response to the deteriorating situation, the company’s directors took measures to stabilise its financial position, including securing a £6.5m capital injection from the shareholder last year, before subsequently exploring potential sale options.

However, with no solvent resolution available, the directors were left with no alternative but to place the business into administration. Following the appointment of joint administrators, production at the company’s two Gateshead sites has come to a halt. The vast majority of the workforce has been made redundant, leaving approximately 170 employees without work. A small number of staff have been retained by the joint administrators to support them in carrying out their duties, reports Chronicle Live.

James Lumb, managing director at Interpath and joint administrator, said: “Zentia has a rich history in the North East, stretching back more than 100 years, and so it’s a tremendous shame that the difficulties facing many businesses in the construction supply chain have resulted in it falling into administration. First and foremost, our thoughts are with the companies’ dedicated staff who have been impacted by redundancy. As a matter of priority, our teams will be providing support to them over the coming days.

“Additionally, we will now be seeking a sale of the companies’ business and assets, including its residual stock, and would encourage any interested parties to make contact with us as soon as possible.”

Interested parties are urged to get in touch with the administrators at zentia@interpath.com.

Just five years ago, the Team Valley tile group — which has also featured amongst the North East’s Top 200 largest companies — was creating new jobs by bringing its manufacturing processes in-house, backed by a £12m finance facility. The company has supplied mineral fibre tiles and grids for suspended ceilings to a range of properties, including offices, schools and hospitals.

It has also played a role in numerous prominent projects across the UK, among them the transformation of Harton Technology College in South Shields and the renovation of Kings Church in Amersham.

This article was written by

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The Newcastle-based housebuilder has seen lower demand in recent weeks after a brighter spring period

Housebuilder Bellway has warned of an uncertain future for the housing market as global issues hit confidence among potential buyers.

The Newcastle-based firm has issued a trading update for the period from February to May in which it said previous guidance on profitability remained. It said spring trading had improved on the picture seen last autumn.

But it highlighted a slowing of customer demand in recent weeks which has been matched by its own caution in land buying. Reservations have fallen on the levels seen during the same period last year.

Bellway added that it was seeing increasing costs from some suppliers as fuel prices and other inflationary pressures weighed on companies. It said that it was “actively managing cost pressures through a combination of disciplined procurement, the introduction of new standard house types, and close control of site production and overheads.”

Chief executive Jason Honeyman said: “Bellway continues to perform robustly in an increasingly challenging market, with customer demand having moderated in recent weeks, after a positive start to the spring selling season. Notwithstanding this, and supported by our forward order book, we are on track to deliver FY26 underlying operating profit within the previously guided range of £320m – £330m.

“The outlook beyond the current financial year remains uncertain, reflecting ongoing geopolitical tensions in the Middle East and a less predictable domestic political environment. Against this backdrop our clear focus on self-help and drive for capital efficiency provides resilience while supporting our strategy to increase cash generation and shareholder returns.”

Bellway said its private reservation rate had decreased by 6.2% to an average of 151 per week while its forward order book had also fallen slightly, to 5,345 homes. Bellway said its land investment “remained disciplined and highly selective” and it was looking to add plots in areas of higher customer demand.

But despite pressures in its market, Bellway is continuing with a £150m share buyback programme launched last year and has increased its interim dividend.

The update said: “We are reiterating our guidance for FY26 volume output of between 9,300 and 9,500 homes, and we remain on track to deliver FY26 underlying operating profit within the previously guided range of £320m – £330m.

“Our industry continues to face challenging headwinds, increasing the risk of a more prolonged period of softer customer demand alongside renewed inflationary pressure on build costs. In response, we are maintaining a sharp focus on the monetisation of our well-invested land bank and work-in-progress position through FY26 and beyond to support improvements in asset turn and cash generation.”

Shares of InterGlobe Aviation, the parent of IndiGo, rose 2% to an intraday high of Rs 4,454 on the BSE on Tuesday after several domestic and global brokerages reiterated their positive outlook on the airline. The bullish stance followed the company’s analyst meet, where management highlighted strong long-term industry growth prospects despite ongoing geopolitical uncertainties in the Middle East.

IndiGo expects strong growth tailwinds for the aviation industry over the next decade, with air passenger traffic projected to more than double between FY26 and FY35. The airline believes growth will be driven by a rising number of first-time international travellers, increasing inbound tourism into India and the development of airport infrastructure, with around 50 new airports expected to be added over the next five years.

Also read: Ghayal hoon isiliye ghatak hoon! Why a global tech crash could be the right medicine for wounded Nifty bulls

To capitalise on this opportunity, the company has outlined an ambitious FY30 vision. IndiGo aims to increase its available seat kilometres (ASK) to 300 billion by FY30, up from 172.4 billion in FY26, implying a 15% CAGR. It also plans to raise passenger traffic to 200 million from 123 million over the same period, reflecting a CAGR of 13%.

What are analysts saying?

Goldman Sachs maintained its Buy rating on InterGlobe Aviation with a target price of Rs 5,300 (21% upside). The brokerage expects FY27 capacity growth to remain in single digits amid fuel price volatility but believes yields will stay resilient despite cost and inflation pressures. It highlighted the airline’s focus on international expansion, targeting a 40% international capacity mix by FY30, supported by an order book of around 900 aircraft. Goldman Sachs also expects yield growth to outpace inflation over the medium term, while cautioning that near-term uncertainty around oil prices and demand could lead to volatility in both earnings and the stock.
Morgan Stanley reiterated its Overweight rating on InterGlobe Aviation with a target price of Rs 5,844 (34% upside), describing IndiGo as one of the world’s best-run airlines with highly competitive non-fuel costs. The brokerage expects FY27 revenue growth to be driven primarily by fares, while capacity growth is likely to remain in single digits. It also highlighted the company’s disciplined premiumisation strategy, which bridges the gap between low-cost and full-service carriers. International operations are expected to account for 40% of the network by FY30, up from 32% in FY26. For Q1 FY27, Morgan Stanley expects passenger revenue growth per seat in the mid-teens on a year-on-year basis.

Also read: Wipro’s Rs 15,000-crore buyback opens June 11; entitlement ratio and key details announced
Motilal Oswal maintained a Buy rating on InterGlobe Aviation with a target price of Rs 5,600, an upside of 28% from current market levels. “Despite persistent near-term headwinds owing to airspace disruptions in the Middle East, high fuel costs and INR depreciation, we remain confident about INDIGO’s growth strategy, anchored by India’s strong domestic demand base and the company’s steadily expanding international network,” the brokerage said. Elara Capital retained its Buy rating on InterGlobe Aviation and assigned a target price of Rs 6,020 (38% upside). The brokerage expects FY27 growth to be led by stronger airfares, while volumes are likely to improve as aircraft deliveries normalise.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

The festival is returning after a hiatus and will be held at Neston Park Estate near Corsham

Road closures have been announced ahead of a major music festival set to take place in Wiltshire this July. Following a break in 2025, Womad has moved from Charlton Park near Malmesbury to a new location at Neston Park Estate, near Corsham.

The World of Music, Arts and Dance festival will run from July 23 to 26, with headliners including London-based soul artist Greentea Peng, Malian singer Oumou Sangaré, Jamaican reggae icon Barrington Levy and Swedish indie‐folk musician José González.

Around 40,000 festivalgoers are expected to attend.

Wiltshire Council has now outlined its approach to managing traffic in the vicinity of the festival site.

In contrast to Charlton Park, the festival’s location between 2007 and 2024, Neston Park’s road network is more limited.

Highways specialists have published their traffic management plan, which will operate between Monday, July 20 and Monday, July 27.

To handle the surge in traffic, they have devised a three-point strategy:

• The speed limit on the A365 between Five Ways and Atworth Lane will be lowered to 30mph.
• Wadswick Lane will be shut from the A365 to the junction with Lower Wadswick.
• And a phased one-way system will be implemented on Ashworth Lane from the A365 to Chapel Lane.

The number of vehicles expected at Neston Park throughout the festival period remains unclear.

Festival organisers are urging music enthusiasts to take a train to Bath, and are developing a shuttle bus service between the station and the venue.

“Unfortunately, it does not appear possible to fully satisfy the demand for fuel at the current moment,” the Kremlin-appointed regional head, Sergei Aksyonov, admitted on 5 June. Hundreds of buses, he said, would not be leaving depots due to shortages.

BOSTON — Shares of Tango Therapeutics Inc. skyrocketed more than 50% on Monday after the clinical-stage biotechnology company reported highly encouraging early results from a Phase 1/2 trial combining its investigational drug vopimetostat with a partner’s therapy in patients with advanced pancreatic cancer.

Tango’s stock closed at $30.93, up $10.71 or 52.97% from Friday’s close of $20.22, hitting an all-time high during the session. The surge came after the company announced initial data showing a 92% objective response rate in a small cohort of patients with MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma treated with vopimetostat plus Revolution Medicines’ daraxonrasib.

The dramatic move reflects investor enthusiasm for potential breakthroughs in treating one of the most lethal forms of cancer. Pancreatic cancer has long frustrated drug developers due to its aggressive nature and limited treatment options, with standard chemotherapy offering modest benefits and significant toxicity.

Tango, based in Boston, focuses on precision oncology using synthetic lethality to target genetic vulnerabilities in cancer cells. Vopimetostat is an MTA-cooperative PRMT5 inhibitor designed to work selectively in tumors with MTAP deletions, which occur in about 40% of pancreatic cancers.

According to data released Monday with a cutoff of May 28, 2026, 12 patients with previously treated PDAC in the vopimetostat plus daraxonrasib arm were response-evaluable. Eleven achieved an objective response, for a 92% ORR, with nine of those confirmed. The disease control rate reached 100%, and the six-month progression-free survival rate was 90%, with median PFS not yet reached.

Results were similarly strong in a small group of non-small cell lung cancer patients, with a 100% ORR among three evaluable patients.

The combination was generally well tolerated. Most treatment-related adverse events were Grade 1 or 2, including rash, stomatitis/mucositis and diarrhea. No discontinuations due to adverse events occurred, though some dose reductions and dose-limiting toxicities were noted at higher levels.

Tango also reported data from vopimetostat combined with Revolution Medicines’ zoldonrasib in PDAC patients, showing a 52% ORR, 74% six-month PFS rate and 96% disease control rate among 27 evaluable patients.

Malte Peters, MD, Tango’s chief executive officer, highlighted the findings in a statement. “In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response,” he said.

Peters added that the durability signals and tolerability support advancing the combination. “Given these data, we intend to prioritize advancement of the vopimetostat plus daraxonrasib combination into Phase 3 development in first-line, MTAP-deleted pancreatic cancer.”

Brian Wolpin, MD, of Dana-Farber Cancer Institute, commented on the potential impact. “These early combination data demonstrated the potential to meaningfully reshape how we treat this disease with a precision-guided, chemotherapy-free approach.”

Pancreatic cancer kills roughly 50,000 Americans annually and has a five-year survival rate below 15%. The disease is often diagnosed late, and options remain limited despite recent advances in targeted therapies for specific mutations.

The trial involved heavily pretreated patients, many with liver metastases and receiving the regimen as third-line therapy. Analysts and investors viewed the results as “unprecedented” for this setting, prompting upgrades from firms like Wolfe Research.

Later in the day, Tango announced a proposed $500 million public offering of common stock to strengthen its balance sheet. The company said proceeds would support pipeline advancement, including the planned Phase 3 trial. Underwriters include J.P. Morgan, Leerink Partners, Cantor and Stifel.

As of the end of the first quarter of 2026, Tango reported a strong cash position of approximately $380 million, which it expected to fund operations into 2028. The new offering would further extend its runway.

Tango’s pipeline centers on MTAP-deleted cancers. Beyond the combinations, the company plans to report additional vopimetostat data in lung cancer and initial results for TNG456 in glioblastoma later in 2026.

The broader biotechnology sector has seen renewed interest in oncology innovation, particularly in KRAS and related pathways long considered “undruggable.” Revolution Medicines’ RAS(ON) inhibitors target mutations present in over 90% of pancreatic cancers.

Wall Street reacted positively. Tango’s market capitalization approached $4.5 billion by Monday’s close. The stock had already risen substantially year-to-date before the announcement, reflecting earlier momentum in its precision medicine approach.

Experts caution that early-phase data in small cohorts require confirmation in larger randomized trials. Pancreatic cancer trials have historically faced high failure rates, but the depth of responses and durability signals here stand out.

Tango said it aims to finalize Phase 3 design in the second half of 2026 and present full data at a scientific conference later this year. The company is also exploring additional combinations.

For patients and families affected by pancreatic cancer, Monday’s news offered a rare note of optimism. While far from a cure, the potential for a targeted, better-tolerated regimen could represent meaningful progress if later trials succeed.

The developments underscore the accelerating pace of innovation in oncology, where genetic insights and combination strategies are opening new avenues against historically intractable diseases. Tango’s rapid stock reaction illustrates how clinical data can swiftly reshape valuations in the biotech space.

Analysts will closely watch regulatory feedback and the details of the Phase 3 plan. Success in front-line pancreatic cancer could position vopimetostat as a cornerstone therapy in this high-unmet-need indication.

Tango Therapeutics continues to execute on its strategy of leveraging synthetic lethality for precision cancer medicines. Monday’s results mark a significant milestone, though the path to approval remains ahead.